Literature DB >> 9694658

DARPP-32: regulator of the efficacy of dopaminergic neurotransmission.

A A Fienberg1, N Hiroi, P G Mermelstein, W Song, G L Snyder, A Nishi, A Cheramy, J P O'Callaghan, D B Miller, D G Cole, R Corbett, C N Haile, D C Cooper, S P Onn, A A Grace, C C Ouimet, F J White, S E Hyman, D J Surmeier, J Girault, E J Nestler, P Greengard.   

Abstract

Dopaminergic neurons exert a major modulatory effect on the forebrain. Dopamine and adenosine 3',5'-monophosphate-regulated phosphoprotein (32 kilodaltons) (DARPP-32), which is enriched in all neurons that receive a dopaminergic input, is converted in response to dopamine into a potent protein phosphatase inhibitor. Mice generated to contain a targeted disruption of the DARPP-32 gene showed profound deficits in their molecular, electrophysiological, and behavioral responses to dopamine, drugs of abuse, and antipsychotic medication. The results show that DARPP-32 plays a central role in regulating the efficacy of dopaminergic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694658     DOI: 10.1126/science.281.5378.838

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  133 in total

1.  Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons.

Authors:  A N Schoffelmeer; L J Vanderschuren; T J De Vries; F Hogenboom; G Wardeh; A H Mulder
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.

Authors:  J A Bibb; Z Yan; P Svenningsson; G L Snyder; V A Pieribone; A Horiuchi; A C Nairn; A Messer; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo.

Authors:  G L Snyder; P B Allen; A A Fienberg; C G Valle; R L Huganir; A C Nairn; P Greengard
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

Review 4.  DeltaFosB: a sustained molecular switch for addiction.

Authors:  E J Nestler; M Barrot; D W Self
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 5.  Psychogenomics: opportunities for understanding addiction.

Authors:  E J Nestler
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

6.  Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain.

Authors:  Hongwen Zhu; Jennifer J O'Brien; James P O'Callaghan; Diane B Miller; Qiang Zhang; Minal Rana; Tiffany Tsui; Youyi Peng; John Tomesch; Joseph P Hendrick; Lawrence P Wennogle; Gretchen L Snyder
Journal:  Brain Res       Date:  2010-04-25       Impact factor: 3.252

Review 7.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

8.  Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

Authors:  Mahomi Kuroiwa; Gretchen L Snyder; Takahide Shuto; Atsuo Fukuda; Yuchio Yanagawa; David R Benavides; Angus C Nairn; James A Bibb; Paul Greengard; Akinori Nishi
Journal:  Psychopharmacology (Berl)       Date:  2011-08-11       Impact factor: 4.530

9.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

10.  GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA.

Authors:  Qing-Rong Liu; Ping-Wu Zhang; Zhicheng Lin; Qi-Fu Li; Amina S Woods; Juan Troncoso; George R Uhl
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.